FDA Approves Continued Access Protocol For HeartMate II Pivotal Trial

Armen Hareyan's picture

Thoratec Corporation said that the FDA has approved an Investigational Device Exemption supplement that allows enrollment of up to an additional 60 patients in the Bridge-to-Transplantation

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.